Miruvor
Sign up
The short answer

What studies of Spirulina (Energy Bits) found

1paper on Spirulina (Energy Bits)
23people in 1 study testing Spirulina (Energy Bits) alone
1randomised trial, the strongest kind of study

At a glance, by condition

Preventing long COVID: D Little or no difference

Based on the strongest evidence, the randomised trial (very low certainty), for overall symptoms.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with Spirulina (Energy Bits) for preventing long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 1 paper.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Spirulina (Energy Bits) · Preventing long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Preventing long COVID

Daily life and health overall

Overall symptoms1 study · 23 people took Spirulina (Energy Bits) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 66 people found no clear difference; a small benefit can't be ruled out.

The randomised trial66 randomised · three-month follow-up · 80 mg/kg daily

No clear difference in overall symptoms.

The evidence is very uncertain about the effect of spirulina (Energy Bits) on overall symptoms later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 66 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Therapeutic Efficacy of Spirulina Algae and N-Acetylcysteine in COVID-19 Hospitalized Patients: A Randomized Phase II Clinical Trial (2024)

    People in the study
    66 randomised
    Dose
    80 mg/kg daily
    Outcome
    frequency of symptoms after discharge in the three-month follow-up
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Side effects

Side effects studies reported2 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Headache1 study
Nausea or stomach upset1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    80 mg at the start

  2. 2Top dose

    Most often 80 mg (1 of 1 studies)

Doses across 1 study

80 to 80 mg.

Each study’s dose, as printed

All papers

  1. Therapeutic Efficacy of Spirulina Algae and N-Acetylcysteine in COVID-19 Hospitalized Patients: A Randomized Phase II Clinical Trial2024 · randomised trial · 66 randomised
    Summary

    The study aimed to evaluate spirulina and N-acetylcysteine in the treatment of hospitalized patients with Coronavirus Disease 2019 (COVID-19). This multicenter, randomized, single-masked, open-label phase II clinical trial enrolled 66 patients with COVID-19. Patients were randomly assigned to one group that received spirulina algae (23 people), one group that received N-acetylcysteine plus spirulina algae (21 people), or a control group (22 people) that received only the national standard treatment for COVID-19. The intervention groups were prescribed 80 mg/kg of spirulina green algae daily; the N-acetylcysteine dose and treatment duration were not reported. The study reported no significant difference between the three groups for duration of hospitalization (P = 0.874), Intensive Care Unit (ICU) admission (P = 0.320), or mortality (P = 0.320). Side effects, including headache (P = 0.022) and nausea (P = 0.039), were significantly less common in the control group. At the three-month follow-up, no statistically significant difference was observed regarding the frequency of symptoms after discharge (P = 0.420). The authors concluded that administering spirulina with or without N-acetylcysteine did not affect length of hospitalization, ICU admission, mortality, and the frequency of symptoms or long COVID. The text does not report limitations.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime